Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...

In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage ...

First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study. Visual PSMA-PET and ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

GREENVILLE, S.C. (WSPA) – September is Prostate Cancer Awareness Month, and doctors emphasize that early detection can save lives. Despite its prevalence, many misconceptions about the disease persist ...